

Routine Screening For ESBL Production, A Necessity Of Today

S Shivaprakasha, K Radhakrishnan, A Gireesh, P Shamsul Karim

Citation

S Shivaprakasha, K Radhakrishnan, A Gireesh, P Shamsul Karim. *Routine Screening For ESBL Production, A Necessity Of Today*. The Internet Journal of Microbiology. 2006 Volume 3 Number 1.

Abstract

Background: Extended spectrum beta lactamases (ESBL) are plasmid mediated enzymes capable of hydrolyzing broad spectrum cephalosporins and monobactams. ESBL producing organisms also show cross resistance to many other antibiotics, limiting therapeutic options.

Aim: To study the frequency of ESBL producers among Enterobacteriaceae, their prevalence in the hospital and their susceptibility pattern to other antibiotics.

Materials And Methods: Between July 2004 to Dec. 2004, a total of 1889 clinically significant Gram negative bacilli belonging to Enterobacteriaceae isolated from various clinical specimens were subjected to screening for ESBL production by standard techniques.

Results: ESBL production was noted in 60.98% (n=1152/1889) of the isolates tested. Percentage of ESBL producers within a species was highest in Enterobacter species 70.9% (n=105/148) followed by Klebsiella species 67.4% (n=439/651) and E.coli 62.34% (n= 568/911). The most frequent ESBL producer was E.coli from ambulatory and ward samples, while from intensive care units it was Klebsiella species. Sensitivity of these isolates to Meropenem was 99.8%, piperacillin tazobactam 96.8%, cefoperazone sulbactam 93.3%.

Conclusion: There is a high prevalence rate of ESBL producers among Enterobacteriaceae. E.coli and Klebsiella species pose a major concern among these. Routine detection of ESBL production in clinical laboratories gives valuable information to the clinician in appropriate selection of antibiotics.

INTRODUCTION

The extended spectrum beta lactamase (ESBL) enzymes are plasmid-mediated enzymes capable of hydrolyzing and inactivating a wide variety of beta lactams, including third generation cephalosporins, penicillins and aztreonam.⁽¹⁾ Plasmids responsible for ESBL production carry resistance to many antibiotics like aminoglycosides, fluoroquinolones, tetracyclines, chloramphenicol and co-trimoxazole.^(2,3) The ESBL producing organisms are reported in increasing numbers worldwide.^(4,5,6,7) National Committee for Clinical Laboratory Standards (NCCLS), now called Clinical Laboratory Standards Institute (CLSI) recommends

screening for ESBL production among E.coli, K.pneumoniae and K.oxytoca.⁽⁸⁾ However, other organisms reported to produce ESBL less frequently are Enterobacter species, Proteus species, Morganella morganii, Serratia marcescens and Pseudomonas aeruginosa.^(9,10)

MATERIALS AND METHODS

Between July 2004 to Dec 2004, a total of 1889 clinically significant Gram negative bacilli belonging to Enterobacteriaceae isolated from various clinical specimens were subjected to ESBL screening. The isolates were identified by standard techniques. Antimicrobial

susceptibility testing was performed by Kirby-Bauer method and interpretation of results was as recommended by NCCLS.(8)

ESBL production was tested by using ceftazidime (30mcg) and ceftazidime plus clavulanic acid (30/10mcg) discs on Mueller-Hinton agar. Organism was considered as an ESBL producer if there was a ≥5mm increase in zone diameter around ceftazidime/clavulanic acid disc compared to zone around ceftazidime disc alone. ESBL production was tested in parallel with the antibiotic susceptibility testing on a separate Mueller Hinton agar plate. As per NCCLS guidelines, an isolate was reported as resistant to all penicillins, cephalosporins and aztreonam, if it was an ESBL producer. *Klebsiella pneumoniae* ATCC 700603 strain was used as ESBL producing control strain, *E.coli* ATCC 25922 was used as ESBL negative control strain. Sample source, patient location and other relevant details were noted. Sample source distribution of ESBL producers is shown in Table 1.

Figure 1

Table 1: Sample source distribution of ESBL producers

Sample	Numbers	Percentage
Urine	517	47.2
Pus	256	23.4
Blood	138	12.6
Respiratory samples	122	11.1
Sterile body fluids	32	2.9
Faecal samples	19	1.7
Genital samples	12	1.1
Total	1096	100

STATISTICAL ANALYSIS

The analysis was done by SPSS (Statistical Package for Social Sciences) version 11. Categorical variables were reported using frequencies and chi-square test was used to analyse the significance of different ESBL producers against the location in the hospital, p value <0.05 was considered significant.

RESULTS

The most frequent Enterobacteriaceae isolated was *E.coli* (48.2%) followed by *Klebsiella* species (34.5%) and *Enterobacter* species (7.8%) [Table 2]. ESBL production was noted in 60.98% (n=1152/1889) of the isolates tested. Among the ESBL producers, urinary isolates were 535 and 617 isolates were from other samples. Percentage of ESBL producers within a species was highest in *Enterobacter* species 70.9% (n=105/148) followed by *Klebsiella* species 67.4% (n=439/651) and *E.coli* 62.3% (n= 568/911). Locationwise distribution of ESBL producers and

predominant organism from different locations of the hospital was analysed. *E.coli* was the most frequent ESBL producer from ambulatory and from ward samples. *Klebsiella* species was the most frequent ESBL producer from intensive care unit samples [table 3].

Figure 2

Table 2 : Frequency of Enterobacteriaceae and ESBL producers

Organism	Total number of isolates(%)	ESBL positive isolates(%)
<i>E.coli</i>	911 (48.2)	568 (62.3)
<i>Klebsiella species</i>	651 (34.5)	439 (67.4)
<i>Enterobacter species</i>	148 (7.8)	105 (70.9)
<i>Citrobacter species</i>	82 (4.3)	25 (30.5)
<i>Proteus species</i>	67 (3.5)	13 (19.4)
<i>Serratia marcescens</i>	11 (0.6)	0
<i>M.morganii</i>	1 (0.05)	0
<i>Salmonella species</i>	14 (0.74)	0
Unidentified	4 (0.21)	2 (50)
Total	1889	1152 (60.98)

Figure 3

Table 3: Locationwise distribution of ESBL producers

Location and sample numbers	<i>E.coli</i>	<i>Klebsiella spp</i>	<i>Enterobacter spp</i>	<i>Citrobacter spp</i>	<i>Proteus spp</i>	Unidentified
Ambulatory (n=185) 16.87%	115	63	10	3	3	0
Ward (n=670) 61.15%	361	262	61	14	9	1
Intensive care unit (n=241) 21.98%	92	114	34	8	1	1

Chi square test : p= 0.001

Sensitivity to meropenem was 99.8% (n=1150/1152), piperacillin tazobactam 96.8% (n=1115/1152), cefoperazone sulbactam 93.3% (n=1075/1152), cotrimoxazole 21.7% (n=250/1152), ciprofloxacin 16.6% (n=191/1152), gentamicin 13.3% (153/1152), amikacin 53% (610/1152). Urinary isolates were tested against nitrofurantoin, norfloxacin, nalidixic acid. These showed susceptibility rate of 66.35% (n=355/535), 16.4% (n=88/535) and 12.3% (n=66/535) respectively [Table 4].

Figure 4

Table 4: Antibiotic susceptibility pattern of ESBL positive isolates

	Antibiotic	Susceptible isolates
All isolates tested (n=1152)	Gentamicin (10mcg)	153 (13.3)
	Ciprofloxacin (5mcg)	191 (16.6)
	Cotrimoxazole (25mcg)	250 (21.7)
	Amikacin (30mcg)	610 (53)
	Cefoperazone-sulbactam (30/75mcg)	1075 (93.3)
	Piperacillin-tazobactam (100/10mcg)	1115 (96.8)
Urine isolates tested (n=535)	Meropenem (10mcg)	1150 (99.8)
	Nalidixic acid (30mcg)	66 (12.3)
	Norfloxacin (10mcg)	88 (16.4)
	Nitrofurantoin (100mcg)	355 (66.4)

DISCUSSION

The frequency of ESBL producers of 60.98% in our study is comparable to previous Indian studies.^(11,12,13) The most frequent isolates in our study were E.coli and Klebsiella species. However, the highest ratio of ESBL production was in Enterobacter species 70.9% (n=105/148). This demonstrates that ESBL screening should not be limited only to E.coli and Klebsiella species. Other species which showed ESBL production were Citrobacter species 30.5% (n=25/82) and Proteus species 19.4% (n=13/67). However, these were infrequent isolates. None of the Salmonella species, Serratia marcescens and Morganella morganii showed ESBL production. Indian studies so far are limited to screening ESBL production among E.coli and K.pneumoniae.^(14,15)

Our study shows that there is a significant difference in the type of organism isolated from different locations of the hospital (p=0.001). The highest number of ESBL producers were E.coli in ambulatory and ward samples, while from intensive care units it was Klebsiella species. This demonstrates that E.coli and Klebsiella species pose a major challenge in hospitalized patients during selection of empirical antibiotic therapy.

It is an established fact that, ESBL producers show cross resistance to other antibiotics also, thus limiting the therapeutic choice. We have noted this in our study as well. Sensitivity to meropenem was almost absolute (99.8%). Sensitivity to piperacillin tazobactam (96.8%) and cefoperazone sulbactam (93.3%) was also good. Whereas sensitivity to gentamicin, ciprofloxacin, co-trimoxazole, nalidixic acid and norfloxacin was poor and not suitable for empirical selection. Urinary isolates showed >50% susceptibility to amikacin and nitrofurantoin. These are the alternative cheaper antibiotics which can be considered for

empirical therapy. The routine susceptibility testing by clinical laboratories fail to detect ESBL positive strains and shows false invitro sensitivity to cephalosporins.⁽¹⁶⁾

Screening for ESBL production as a routine procedure in clinical laboratories gives valuable information to the clinician in appropriate selection of antibiotics. Hence, we conclude based on our study that, there is a high prevalence rate of ESBL producers among Enterobacteriaceae. E.coli and Klebsiella species pose a major concern among these. Based on the prevalence rate of the ESBL producers in a healthcare facility, antibiotic policy of the institution can be tailored to achieve superior therapeutic outcome and bring about a reduction in healthcare costs. It also eliminates misuse of conventional cephalosporins in a significant proportion of patients.

CORRESPONDENCE TO

Dr.Shashikala.S.,M.D Asst. Professor, Department of Microbiology, Amrita Institute of Medical Sciences and Research Centre, Kochi, Kerala-PIN-682 026 India Tel : 04842801234, 04845008010 Fax : 04842802020 shashikalas@aims.amrita.edu

References

1. Antimicrobial susceptibility testing. In:Elmer W Koneman, Stephen D Allen, William M Janda, Paul C Schreckenger, Washington C Winn Jr., editors. Colour Atlas and text book of Diagnostic Microbiology. 5th edn. Philadelphia: Lippincott Williams & Wikins; 1997. pp. 785-856.
2. Jacoby GA, Sutton L. Properties of plasmids responsible for production of extended-spectrum B-lactamases. Antimicrob Agents Chemother 1991; 35: 164-69.
3. Nathisuwan S, Burgess DS, Lewis II JS. ESBLs: Epidemiology, Detection and Treatment. Pharmacotherapy 2001; 2: 920-28.
4. Jarlier V, Nicolas M, Fournier G, Philippon A. Extended broad-spectrum -lactamases conferring transferable resistance to newer -lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns. Rev Infect Dis 1988; 10: 867-78.
5. Livermore DM, Yuan M. Antibiotic resistance and production of extended spectrum b-lactamases amongst Klebsiella spp. from intensive care units in Europe. J Antimicrob Chemother 1996; 38: 409-24.
6. Bantar C, Famiglietti A, Goldberg M. Three-year surveillance study of nosocomial bacterial resistance in Argentina. The Antimicrobial Committee; and the National Surveillance Program (SIR) Participants Group. Int J Infect Dis 2000; 4: 85-90.
7. Zaman G, Karamat KA, Abbasi S, Rafi S, Ikram A. Prevalence of Extended-spectrum beta-lactamase (ESBL) producing Enterobacteriaceae in nosocomial isolates. PAFMJ 1999; 49: 91-6.
8. Performance standards for antimicrobial susceptibility testing. Fourteenth informational supplement M 100-S14. NCCLS 2004, Wayne, PA.
9. Louis B. Rice, Daniel Sahm, and Robert A. Bonomo. Mechanism of Resistance in Antibacterial agents. In: Patrick

R Murray, Ellen Jo Baron, James H Jorgensen, Michael A Pfaller, Robert H Yolken editors. Manual of Clinical Microbiology. 8th edn. Washington DC:ASM press; 2003. pp. 1074-1101.

10. Hsueh PR, Chen ML, Sun CC, Pan HJ, Yang LS, Ho SW et al. Emergence of antimicrobial drug resistance of major pathogens causing nosocomial infections at a university hospital in Taiwan 1981-1999. *Emerg Infect Dis* 2002; 8: 63-8.

11. Singhal S, Mathur T, Khan S, Upadhyay DJ, Chug S, Gaiind R et al. Evaluation of methods for Amp-C beta-lactamase in gram negative clinical isolates from tertiary care hospitals. *Indian J Med Microbiol* 2005; 23: 120-24.

12. Srujana Mohanty, Ritu Singhal, Seema Sood, Benu Dhawan, Bimal K. Das, Arti Kapil. Comparative in vitro activity of beta-lactam/beta-lactamase inhibitor against gram

negative bacteria. *Indian J Med Res* 2005; 122: 425-28.

13. Mathur P, Tatman A, Das B. Prevalence of extended beta lactamase producing gram negative bacteria in a tertiary care hospital. *Indian J Med Res* 2002;115: 153-57.

14. Babypadmini S, Appalaraju B. Extended spectrum - lactamases in urinary isolates of *Escherichia coli* and *Klebsiella pneumoniae* - prevalence and susceptibility pattern in a tertiary care hospital. *Indian J Med Microbiol* 2004; 22: 172-74.

15. Subha A, Ananthan S. Extended spectrum beta lactamase (ESBL) mediated resistance to third generation cephalosporins among *Klebsiella pneumoniae* in Chennai. *Indian J Med Microbiol* 2002; 20: 92-5.

16. Chaudhary U, Aggarwal R. Extended spectrum - lactamases (ESBL) - An emerging threat to clinical therapeutics. *Indian J Med Microbiol* 2004; 22: 75-80.

Author Information

Shashikala Shivaprakasha, M.D (Microbiology)

Dept. of Microbiology, Amrita Institute of Medical Sciences

Kavitha Radhakrishnan, M.D (Microbiology)

Dept. of Microbiology, Amrita Institute of Medical Sciences

A. R. Gireesh, M.Sc (Med.Microbiology)

Dept. of Microbiology, JIPMER

P. M. Shamsul Karim, M.D (Microbiology)

Dept. of Microbiology, Amrita Institute of Medical Sciences